MARKET

TYRA

TYRA

Tyra Biosciences, Inc.
NASDAQ
31.88
+0.94
+3.04%
After Hours: 31.88 0 0.00% 16:36 06/26 EDT
OPEN
30.92
PREV CLOSE
30.94
HIGH
32.26
LOW
30.08
VOLUME
4.23M
TURNOVER
--
52 WEEK HIGH
40.65
52 WEEK LOW
8.98
MARKET CAP
1.90B
P/E (TTM)
-14.6622
1D
5D
1M
3M
1Y
5Y
1D
Tyra Biosciences (TYRA) Gains Attention On Phase II Results, Is The Upside Already Priced In?
Simply Wall St · 3d ago
Analysts Offer Insights on Healthcare Companies: Palvella Therapeutics (PVLA), Tyra Bioscience (TYRA) and Revolution Medicines (RVMD)
TipRanks · 3d ago
Weekly Report: what happened at TYRA last week (0615-0619)?
Weekly Report · 6d ago
Analysts Are Bullish on Top Healthcare Stocks: ClearPoint Neuro (CLPT), Tyra Bioscience (TYRA)
TipRanks · 06/18 12:50
Tyra Biosciences Initiated at Buy by Jones Trading
Dow Jones · 06/17 13:51
Tyra Biosciences Price Target Announced at $56.00/Share by Jones Trading
Dow Jones · 06/17 13:51
Tyra Bioscience (TYRA) Receives a Buy from Oppenheimer
TipRanks · 06/17 11:57
Tyra Biosciences assumed with an Outperform at Oppenheimer
TipRanks · 06/17 11:55
More
About TYRA
Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision medicines that target opportunities in FGFR biology. Its in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help it design and predict which candidates may demonstrate highest potency, selectivity and tolerability in clinic. Its expertise in FGFR biology has created a pipeline with clinical-stage programs in targeted oncology and genetically defined conditions. Its lead precision medicine stemming from SNAP, oral dabogratinib, is a potential first-in-class selective FGFR3 inhibitor in development for LG-UTUC, IR NMIBC and ACH. It is also developing TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers, in SURF431 study (advanced hepatocellular carcinoma), and TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in SURF201 study (metastatic intrahepatic cholangiocarcinoma).

Webull offers Tyra Biosciences Inc stock information, including NASDAQ: TYRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TYRA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TYRA stock methods without spending real money on the virtual paper trading platform.